152 related articles for article (PubMed ID: 6674914)
1. Correlation between biochemical tests, parameters of drug elimination and hepatic enzyme induction in chronic liver diseases.
Horváth T; Pár A; Beró T; Kádas I; Fábián C; Jávor T
Acta Med Hung; 1983; 40(4):203-13. PubMed ID: 6674914
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of hepatic drug metabolism by (+)-cyanidanol-3 (Catergen) in chronic alcoholic liver disease.
Pár A; Horváth T; Beró T; Kádas I; Pakodi F; Jávor T
Acta Physiol Hung; 1984; 64(3-4):449-54. PubMed ID: 6152369
[TBL] [Abstract][Full Text] [Related]
3. Investigation of biotransformation capacity in patients with chronic liver diseases by pharmacokinetic methods: experimental trials.
Horváth T; Past T; Tatai Z; Pár A; Kádas I; Tapsonyi Z; Jávor T
Pol J Pharmacol Pharm; 1984; 36(4):361-71. PubMed ID: 6396596
[TBL] [Abstract][Full Text] [Related]
4. Drug metabolism in alcoholic liver disease.
Horváth T; Pár A; Past T; Tapsonyi Z; Ruzsa C; Kádas I; Jávor T
Acta Med Acad Sci Hung; 1982; 39(3-4):169-77. PubMed ID: 7185242
[No Abstract] [Full Text] [Related]
5. Impairment of drug elimination in patients with liver disease.
Narang AP; Datta DV; Mathur VS
Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):28-32. PubMed ID: 3988389
[TBL] [Abstract][Full Text] [Related]
6. Disorders of biotransformation during the progression of alcoholic liver disease.
Horváth T; Pár A; Past T; Beró T; Tapsonyi Z; Kádas I
Acta Med Hung; 1986; 43(4):351-7. PubMed ID: 3601579
[TBL] [Abstract][Full Text] [Related]
7. Human tolerance of flumecinol (Zixoryn, RGH-3332), its regime and dosage in healthy volunteers.
Vezekenyi Z; Ferenci J; Radnai B; Horvath T; Past T; Nagy L; Jávor T
Int J Clin Pharmacol Res; 1983; 3(2):77-88. PubMed ID: 6679516
[TBL] [Abstract][Full Text] [Related]
8. Beta-adrenoceptor blocking drugs and cytochrome P-450: the influence of propranolol treatment on caffeine, antipyrine, D-glucaric acid and indocyanine green elimination in patients with hepatic disorders.
Traeger A; Horváth T; Rechenbach C; Jávor T
Int J Clin Pharmacol Res; 1986; 6(3):235-9. PubMed ID: 3744626
[TBL] [Abstract][Full Text] [Related]
9. Sulfadimidine kinetics in patients with various chronic liver diseases.
Horváth T; Past T; Par A; Kádas I; Jávor T
Pol J Pharmacol Pharm; 1988; 40(3):257-64. PubMed ID: 3241767
[TBL] [Abstract][Full Text] [Related]
10. Proceedings: The influence of chronic liver disease on the elimination of d-propranolol, anti-pyrine, and indocyanine green.
Branch RA; James JA; Read AE
Gut; 1974 Oct; 15(10):837-8. PubMed ID: 4434964
[No Abstract] [Full Text] [Related]
11. Liver function and medroxyprogesterone acetate elimination in man.
Rautio A
Biomed Pharmacother; 1984; 38(4):199-204. PubMed ID: 6498308
[TBL] [Abstract][Full Text] [Related]
12. [Hepatic elimination of indocyanine green and antipyrine in patients with chronic liver disease].
Kuntz HD; Meessen D; May B
Med Welt; 1982 Jun; 33(25):909-10. PubMed ID: 7109938
[No Abstract] [Full Text] [Related]
13. Effect of alphamethyldopa on the half-lives of antipyrine, tolbutamide and D-glucaric acid excretion in man.
Gachályi B; Tornyossy M; Vas A; Káldor A
Int J Clin Pharmacol Ther Toxicol; 1980 Mar; 18(3):133-5. PubMed ID: 6103880
[TBL] [Abstract][Full Text] [Related]
14. Note on the enzyme assay for urinary D-glucaric acid and correlation with rifampicin-induced mixed function oxidase activity.
Perry W; Jenkins MV
Int J Clin Pharmacol Ther Toxicol; 1986 Nov; 24(11):609-13. PubMed ID: 3793294
[TBL] [Abstract][Full Text] [Related]
15. Predictors of mortality in hepatic encephalopathy in acute and chronic liver disease: a preliminary observation.
Udayakumar N; Subramaniam K; Umashankar L; Verghese J; Jayanthi V
J Clin Gastroenterol; 2007; 41(10):922-6. PubMed ID: 18090162
[TBL] [Abstract][Full Text] [Related]
16. Disturbances of iron metabolism in chronic liver diseases.
Sikorska K; Stalke P; Lakomy EA; Michalska Z; Witczak-Malinowska K; Stolarczyk J
Med Sci Monit; 2003 Aug; 9 Suppl 3():64-7. PubMed ID: 15156616
[TBL] [Abstract][Full Text] [Related]
17. Serum leptin levels in patients with nonalcoholic chronic liver disease.
Nakamuta M; Tada S; Uchimura K; Enjoji M; Kinukawa N; Iwamoto H; Sugimoto R; Shimada M; Ohashi M; Sugimachi K; Nawata H
Hepatogastroenterology; 2001; 48(38):527-32. PubMed ID: 11379347
[TBL] [Abstract][Full Text] [Related]
18. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
Branch RA; James JA; Read AE
Clin Pharmacol Ther; 1976 Jul; 20(1):81-9. PubMed ID: 1277728
[TBL] [Abstract][Full Text] [Related]
19. Liver size in evaluating drug metabolizing capacity in man.
Pirttiaho H
Int J Clin Pharmacol Biopharm; 1979 Jun; 17(6):271-6. PubMed ID: 468452
[TBL] [Abstract][Full Text] [Related]
20. Antipyrine clearance and its correlation to routine liver function tests in patients with liver disease.
Krausz Y; Zylber-Katz E; Levy M
Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):253-7. PubMed ID: 7450926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
